CK-MB mass test in ischemic myocardial injury. Comparison of two tests: BioMerieux Vidas and sanofi access immunoassays.
The analytical and clinical performances of the new fluorescent immunoassay (CK-MB mass Vidas-BioMerieux) were examined and compared to the chemiluminescent test (CK-MB mass Access-Sanofi-Pasteur). Assay precisions of the CK-MB Vidas test within-assay or between-assay were less than 5.4 and 5.3%, respectively. Linearity was tested up to 214 microg/L. The CK-MB Vidas test was free of interference with CK-BB, CK-MM, and macro-CK. One hundred nineteen blood samples from patients with ischemic myocardial injury (IMI): acute myocardial infarction (AMI), suspected myocardial contusion (SMC), and unstable angina pectoris (UA), were tested using both immunoassays. In AMI, a good correlation was found (Y [CK-MB Access] = 1.1372 x [CK-MB Vidas] - 6.3902; r(2) = 0.96). In UA and SMC, low values were observed and both methods were well correlated (Y [CK-MB Access] = 1.3662 x [CK-MB Vidas] + 0.0671; r(2) = 0.97). Clinical data were in good agreement with both immunoassays. ROC analysis performed in AMI demonstrated that the clinical performances of the two assays were similar.
Poirey
S
S
Department of Biochemistry, CHU, Nimes, France.
Polge
A
A
Bertinchant
J P
JP
Bancel
E
E
Boyer
J C
JC
Fabbro-Peray
P
P
de Bornier
B M
BM
Ledermann
B
B
Bonnier
M
M
Bali
J P
JP
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000787:Angina Pectoris / Q000201:enzymology; D003402:Creatine Kinase / Q000097:blood*; D005260:Female; D015200:Fluoroimmunoassay; D006801:Humans; D007118:Immunoassay / Q000379:methods*; D007527:Isoenzymes; D008163:Luminescent Measurements; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000201:enzymology; D017202:Myocardial Ischemia / Q000201:enzymology*; D011786:Quality Control; D012372:ROC Curve; D012680:Sensitivity and Specificity
D007527:Isoenzymes; D003402:Creatine Kinase